跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/PER-016-17
PER-016-17已完成未知

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATOR-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS TO ORAL DELAFLOXACIN IN ADULT SUBJECTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA

Melinta Therapeutics, Inc.,0 个研究点目标入组 4 人开始时间: 2017年7月26日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
未知
状态
已完成
入组人数
4
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • •1.Male and female subjects 18 years of age or older.
  • •Patients from a nursing home setting may be enrolled if they are normally ambulatory and are not on enteral feeding
  • •2.Evidence of acute onset of CABP.
  • •Subjects must have at least 2 of the following clinical signs and symptoms (new or worsening):
  • •Production of purulent sputum consistent with a bacterial infection
  • •Difficulty breathing (dyspnea)
  • •Chest pain due to pneumonia
  • •Subjects must also have at least 2 of the following findings:
  • •Fever (oral temperature > 38°C or equivalent) within 24 hours prior to randomization
  • •Hypothermia (oral temperature < 35°C or equivalent) within 24 hours prior to randomization
  • •Tachycardia (> 100 beats per minute)
  • •Tachypnea (elevated respiratory rate >18 breaths per minute)
  • •Subjects must also have at least 1 of the following findings:
  • •Hypoxemia (oxygen saturation < 90% or PaO2 < 60 mmHg on room air or with subject’s baseline [pre-CABP under study] supplemental oxygen flow rate)
  • •Clinical evidence of pulmonary consolidation and/or presence of pulmonary rales
  • •An elevated white blood cell count (WBC) > 10,000/mm3 or 15% immature neutrophils (bands), regardless of total peripheral WBC count or leukopenia with WBC < 4500/mm3
  • •3.Presence of lobar, multilobar, or patchy parenchymal infiltrate(s) consistent with acute bacterial pneumonia on a pulmonary imaging study (e.g., chest radiograph [CXR] [posteroanterior and lateral preferred; single view acceptable if conclusive] or computed tomography [CT] of thorax) as per local standard of care within 48 hours before the first dose of study drug.
  • •4.PORT risk class of II, III, IV, or V PSI score (greater than 50). Subjects may be initially screened based on meeting CURB-65 score of 2 to 4. PORT risk class II will be limited to 25% of randomized subjects.
  • •5.In the opinion of the investigator, the subject must be a suitable candidate for possible IV to oral switch antibiotic therapy and must also be able to swallow large tablets/capsules intact without crushing.
  • •6.Females of childbearing potential (including females less than 2 years post-menopausal) must have a negative pregnancy test prior to enrollment. Sexually active women and men with partners of childbearing potential must agree to use an acceptable form of contraception, as determined by the investigator (e.g., abstinence, oral contraceptives, double barrier methods, hormonal injectable, transdermal, or implanted contraceptives, tubal ligation, or vasectomy) during participation in the study and through the Follow-up Visit (Day 28). Female partners of male subjects should also use an additional reliable method of contraception, such as spermicide with male or female condoms, cervical sponge, intrauterine device, cervical cap or diaphragm, or oral, implantable, transdermal, or injectable contraceptives during study and through the Follow-up Visit (Day 28).
  • •7.In the opinion of the investigator, the subject must be able and willing to comply with protocol requirements.
  • •8.A written, voluntarily signed informed consent must be obtained from the subject or where allowed by local regulations, legally authorized representative, in accordance with local regulations, before the initiation of any study-related procedures. The subject or legally authorized representative must be able to read and/or understand the informed consent form

排除标准

  • •1.Medical history of significant hypersensitivity or allergic reaction to antibiotics of the quinolone or oxazolidinone class or study drug excipients according to the judgment of the investigator.
  • •2.Women who are pregnant or lactating.
  • •3.Any infection expected to require other systemic antibacterial agents in addition to study drug.
  • •4.Receipt of systemic antibiotic therapy in the 7 days before enrollment unless one of the following is documented:
  • •The subject received at least 48 hours of antibiotic therapy for CABP and the clinic notes document treatment failure (i.e., not by patient history or pulmonary imaging alone) with new or worsening symptoms while on pre-study therapy or identification of a respiratory pathogen that is resistant to a pre-study antibiotic, which would be susceptible to study drug (delafloxacin or moxifloxacin) in subjects with new or worsening signs and symptoms of CABP.
  • •The subject received 1 dose of a single, potentially effective, short-acting antimicrobial drug or a short-acting antimicrobial drug regimen for treatment of the CABP under study within 24 hours of enrollment. (Note: 1 dose of a regimen is defined as the standard therapy for CABP at the study site.) Subjects who received prior antimicrobial drug under this criterion will be limited to no more than 25% of total randomized subjects.
  • •5.Respiratory infection confirmed or suspected to be secondary to hospital-acquired or ventilator-associated pneumonia or that requires treatment in an intensive care setting at the time of informed consent.
  • •6.Intubated at the time of informed consent or clinical presentation with pneumonia that would require invasive mechanical ventilation.
  • •7.Current or suspected diagnosis of:
  • •Viral pneumonia, fungal pneumonia, including Pneumocystis jiroveci pneumonia
  • •Aspiration pneumonia
  • •Other noninfectious causes of pulmonary infiltrates (e.g., pulmonary embolism, hypersensitivity pneumonia, congestive heart failure)
  • •Primary or metastatic lung cancer
  • •Cystic fibrosis
  • •Active or suspected tuberculosis
  • •Empyema (not including sterile parapneumonic effusions)
  • •8.Known anatomical or pathological bronchial obstruction or a history of bronchiectasis or documented Global initiative for chronic Obstructive Lung Disease (GOLD) Stage 4 chronic obstructive pulmonary disease or a history of post obstructive pneumonia.
  • •9.Severely compromised immune system, e.g.:
  • •Known absolute neutropenia (absolute neutrophil count < 500 cells/µL)
  • •Known human immunodeficiency virus infection (HIV) with a CD4 count < 350 cells/µL within the last 4 months
  • •Cancer chemotherapy or radiation in the last 3 months
  • •Hematological malignancy
  • •Bone marrow transplantation
  • •Chronic steroid use (> 20 mg prednisone per day or equivalent) prior to enrollment
  • •10.Known history of Child-Pugh Class B or C liver disease and/or presence or possible signs of significant hepatic disease or alanine aminotransferase (ALT) > 3× the upper limit of normal (ULN).
  • •11.Severe renal disease or creatinine clearance (CrCl) ≤ 29 mL/min using Cockcroft-Gault formula or need for hemodialysis or peritoneal dialysis.
  • •12.Uncorrected hypokalemia or known uncorrected hypomagnesemia at time of enrollment.
  • •13.Ongoing treatment for seizures or untreated history of seizures.
  • •14.History of peripheral neuropathy.
  • •15.History of tendon damage/disord

研究者

相似试验

进行中（未招募）
1 期
A study to evaluate the efficacy and safety ofbimekizumab in subjects with activenonradiographic axial spondyloarthritisonradiographic axial spondyloarthritisMedDRA version: 20.0Level: LLTClassification code 10076297Term: Non-radiographic axial spondyloarthritisSystem Organ Class: 100000004859
EUCTR2017-003064-13-BGCB Biopharma SR240
进行中（未招募）
1 期
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q (MDS-005)TRANSFUSION-DEPENDENT ANEMIA DUE TO IPSS LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES WITHOUT DELETION 5Q [31] AND UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTMedDRA version: 19.0Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864
EUCTR2009-011513-24-BECelgene Corporation228
招募中
不适用
SAFETY AND IMMUNOGENICITY OF V114 IN ADULTS INFECTED WITH HIV-J13 Pneumonia due to Streptococcus pneumoniaePneumonia due to Streptococcus pneumoniaeJ13
PER-021-18Merck Sharp & Dohme Corp., una subsidiaria de Mer·ck & Co. Inc.,
进行中（未招募）
1 期
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE (PROGRESS)
EUCTR2018-004337-32-GBAllergan Limited750
进行中（未招募）
1 期
A MAINTENANCE STUDY OF THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN ULCERATIVE COLITISModerately to Severely Active Ulcerative ColitisMedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856
EUCTR2017-003238-96-GBEli Lilly and Company1,044
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,... | 临床试验